



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



ASP2905

Item No. 40780

CAS Registry No.: 792184-90-8
Formal Name: N²-(4-fluorophenyl)-N⁴-phenyl-N⁶-(2-pyrimidinylmethyl)-1,3,5-triazine-2,4,6-triamine
MF: C₂₀H₁₇FN₈
FW: 388.4
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

ASP2905 is supplied as a solid. A stock solution may be made by dissolving the ASP2905 in the solvent of choice, which should be purged with an inert gas. ASP2905 is soluble (≥10 mg/ml) in DMSO.

Description

ASP2905 is an inhibitor of voltage-gated potassium channel K_v12.2.¹ It inhibits potassium currents in CHO cells expressing K_v12.2 (IC₅₀ = 9 nM). ASP2905 is selective for K_v12.2 over 55 transmembrane proteins at 10 μM. It reduces the frequency of spontaneous inhibitory postsynaptic currents (IPSCs) in primary rat hippocampal neurons when used at concentrations of 0.1 and 1 μM. ASP2905 increases dopamine and acetylcholine efflux in the rat medial prefrontal cortex and improves latent learning in the water-finding task in mice.² It also reduces hyperlocomotion induced by phencyclidine (PCP) in mice when administered at doses of 0.03, 0.1, and 0.3 mg/kg and reduces PCP-induced increases in immobility in mice in the forced swim test at 0.01 and 0.1 mg/kg.³

References

1. Takahashi, S., Inamura, K., Yarimizu, J., *et al.* Neurochemical and neuropharmacological characterization of ASP2905, a novel potent selective inhibitor of the potassium channel KCNH3. *Eur. J. Pharmacol.* **810**, 26-35 (2017).
2. Takahashi, S., Ohmiya, M., Honda, S., *et al.* The KCNH3 inhibitor ASP2905 shows potential in the treatment of attention deficit/hyperactivity disorder. *PLoS One* **13(11)**, e0207750 (2018).
3. Takahashi, S., Okamura, A., Yamazaki, M., *et al.* ASP2905, a specific inhibitor of the potassium channel Kv12.2 encoded by the *Kcnh3* gene, is psychoactive in mice. *Behav. Brain Res.* **378**:112315, (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/26/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM